Profiling Basal Forebrain Cholinergic Neurons Reveals a Molecular Basis for Vulnerability Within the Ts65Dn Model of Down Syndrome and Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Basal forebrain cholinergic neuron (BFCN) degeneration is a hallmark of Down syndrome (DS) and Alzheimer’s disease (AD). Current therapeutics have been unsuccessful in slowing disease progression, likely due to complex pathological interactions and dysregulated pathways that are poorly understood. The Ts65Dn trisomic mouse model recapitulates both cognitive and morphological deficits of DS and AD, including BFCN degeneration. We utilized Ts65Dn mice to understand mechanisms underlying BFCN degeneration to identify novel targets for therapeutic intervention. We performed high-throughput, single population RNA sequencing (RNA-seq) to interrogate transcriptomic changes within medial septal nucleus (MSN) BFCNs, using laser capture microdissection to individually isolate ~500 choline acetyltransferase-immunopositive neurons in Ts65Dn and normal disomic (2N) mice at 6 months of age (MO). Ts65Dn mice had unique MSN BFCN transcriptomic profiles at ~6 MO clearly differentiating them from 2N mice. Leveraging Ingenuity Pathway Analysis and KEGG analysis, we linked differentially expressed gene (DEG) changes within MSN BFCNs to several canonical pathways and aberrant physiological functions. The dysregulated transcriptomic profile of trisomic BFCNs provides key information underscoring selective vulnerability within the septohippocampal circuit. We propose both expected and novel therapeutic targets for DS and AD, including specific DEGs within cholinergic, glutamatergic, GABAergic, and neurotrophin pathways, as well as select targets for repairing oxidative phosphorylation status in neurons. We demonstrate and validate this interrogative quantitative bioinformatic analysis of a key dysregulated neuronal population linking single population transcript changes to an established pathological hallmark associated with cognitive decline for therapeutic development in human DS and AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Complement and microglia mediate early synapse loss in Alzheimer mouse models
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., et al. (2016) · Science · doi:10.1126/science.aad8373 · Cited by 3,343 · cited 1×
“Changes inDlg4 have been linked to early synapse loss in AD mouse models and human postmortem AD studies [122, 123].”
BackgroundApolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425 · cited 1×
“The Apoe e4 isoform is known to drive AD pathology [70].”
BackgroundMitochondria and Mitochondrial Cascades in Alzheimer’s disease
Swerdlow, R. H. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170585 · Cited by 850
A Prospective Study of Alzheimer Disease in Down Syndrome
Lai, F., & Williams, R. S. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520440031017 · Cited by 561
Colangelo, V., Schurr, J., Ball, M. J., Pelaez, R. P., Bazan, N. G., & Lukiw, W. J. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10351 · Cited by 517
Kleschevnikov, A. M., Belichenko, P. V., Villar, A. J., Epstein, C. J., Malenka, R. C., & Mobley, W. C. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1766-04.2004 · Cited by 459
The hippocampus and related neocortical structures in memory transformation
Sekeres, M. J., Winocur, G., & Moscovitch, M. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.05.006 · Cited by 370 · cited 1×
“Interrogating memory requires a complex paradigm that involves multiple circuits in the brain, including memory consolidation in the locus coeruleus [24, 25], serotonergic neurons of the median raphe nucleus which affect memory formation [26], medial prefrontal cortex pyramidal neurons [27], and cholinergic projection…”
BackgroundCooper, J. D., Salehi, A., Delcroix, J.-D., Howe, C. L., Belichenko, P. V., Chua-Couzens, J., Kilbridge, J. F., Carlson, E. J., Epstein, C. J., & Mobley, W. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181219298 · Cited by 336 · cited 2×
“BFCN changes begin approximately at 6 months of age (MO) [21, 31, 32, 41].”
BackgroundSynaptic structural abnormalities in the Ts65Dn mouse model of down syndrome
Belichenko, P. V., Masliah, E., Kleschevnikov, A. M., Villar, A. J., Epstein, C. J., Salehi, A., & Mobley, W. C. (2004) · Journal of Comparative Neurology · doi:10.1002/cne.20337 · Cited by 297
Down syndrome and Alzheimer's disease: common pathways, common goals
Hartley, D., Blumenthal, T., Carrillo, M., DiPaolo, G., Esralew, L., Gardiner, K., Granholm, A.-C., Iqbal, K., Krams, M., Lemere, C., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.007 · Cited by 290 · cited 1×
“D Volcano plots show relative upregulation, downregulation, and LFC of Ts MSN BFCN gene expression differences on a –log [10] of p value scale.”
BackgroundCataldo, A. M., Petanceska, S., Peterhoff, C. M., Terio, N. B., Epstein, C. J., Villar, A., Carlson, E. J., Staufenbiel, M., & Nixon, R. A. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-17-06788.2003 · Cited by 241 · cited 1×
“BFCN changes begin approximately at 6 months of age (MO) [21, 31, 32, 41].”
BackgroundDuchon, A., Raveau, M., Chevalier, C., Nalesso, V., Sharp, A. J., & Herault, Y. (2011) · Mammalian Genome · doi:10.1007/s00335-011-9356-0 · Cited by 224 · cited 2×
“We queried DS murine orthologs triplicated in the Ts mouse model [67, 85], and 64 protein coding trisomic genes were expressed in MSN BFCNs.”
MethodAltered long-term potentiation in the young and old Ts65Dn mouse, a model for down syndrome
Siarey, R. J., Stoll, J., Rapoport, S. I., & Galdzicki, Z. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(97)00157-3 · Cited by 222
Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome
Siarey, R. J., Carlson, E. J., Epstein, C. J., Balbo, A., Rapoport, S. I., & Galdzicki, Z. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00083-0 · Cited by 184
Costa, A. C. S., & Grybko, M. J. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.03.031 · Cited by 174
Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities
Rueda, N., Flórez, J., & Martínez-Cué, C. (2012) · Neural Plasticity · doi:10.1155/2012/584071 · Cited by 171
Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of down syndrome.
Belichenko, P. V., Kleschevnikov, A. M., Masliah, E., Wu, C., Takimoto‐Kimura, R., Salehi, A., & Mobley, W. C. (2009) · Journal of Comparative Neurology · doi:10.1002/cne.21895 · Cited by 141
Kleschevnikov, A. M., Belichenko, P. V., Gall, J., George, L., Nosheny, R., Maloney, M. T., Salehi, A., & Mobley, W. C. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.10.009 · Cited by 124
Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions
Sturgeon, X., & Gardiner, K. J. (2011) · Mammalian Genome · doi:10.1007/s00335-011-9321-y · Cited by 117 · cited 1×
“We queried DS murine orthologs triplicated in the Ts mouse model [67, 85], and 64 protein coding trisomic genes were expressed in MSN BFCNs.”
MethodGinsberg, S. D., Elarova, I., Ruben, M., Tan, F., Counts, S. E., Eberwine, J. H., Trojanowski, J. Q., Hemby, S. E., Mufson, E. J., & Che, S. (2004) · Neurochemical Research · doi:10.1023/b:nere.0000023593.77052.f7 · Cited by 97
Self-citationLocus Coeruleus and Dopamine-Dependent Memory Consolidation
Yamasaki, M., & Takeuchi, T. (2017) · Neural Plasticity · doi:10.1155/2017/8602690 · Cited by 91
Kaur, G., Sharma, A., Xu, W., Gerum, S., Alldred, M. J., Subbanna, S., Basavarajappa, B. S., Pawlik, M., Ohno, M., Ginsberg, S. D., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.5338-13.2014 · Cited by 58
Self-citation
Cited by
Hemonnot-Girard, A.-L., Meersseman, C., Pastore, M., Garcia, V., Linck, N., Rey, C., Chebbi, A., Jeanneteau, F., Ginsberg, S. D., Lachuer, J., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02581-0 · Cited by 24
“Our results further expand the value of the approach as here we show that a short staining protocol can be added to the procedure to allow isolation and transcriptome analysis of spatially distinct cell subtypes [55].”
BackgroundSelf-citationXing, Z., Li, Y., Cortes-Gomez, E., Jiang, X., Gao, S., Pao, A., Shan, J., Song, Y., Perez, A., Yu, T., et al. (2023) · Human Molecular Genetics · doi:10.1093/hmg/ddad056 · Cited by 23
Rodent Modeling of Alzheimer's Disease in Down Syndrome: In vivo and ex vivo Approaches
Farrell, C., Mumford, P., & Wiseman, F. K. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.909669 · Cited by 22
Metadata
- Authors
- Alldred, M. J., Penikalapati, S. C., Lee, S. H., Heguy, A., Roussos, P., & Ginsberg, S. D.
- Venue
- Molecular Neurobiology
- Published
- 2021-07-14
- Volume
- 58
- Issue
- 10
- Pages
- 5141-5162
- ISSN
- 0893-7648 (ISSN-L)
- 1559-1182
- OpenAlex
- W3137716996
- Cited by
- 35
- References
- 22
- FWCI
- 4.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.